Submission Details
| 510(k) Number | K230096 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 13, 2023 |
| Decision Date | May 23, 2023 |
| Days to Decision | 130 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
K230096 is an FDA 510(k) clearance for the Genius AI Detection 2.0 with CC-MLO Correlation, a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II — Special Controls, product code QDQ), submitted by Hologic, Inc. (Marlborough, US). The FDA issued a Cleared decision on May 23, 2023, 130 days after receiving the submission on January 13, 2023. This device falls under the Radiology review panel. Regulated under 21 CFR 892.2090.
| 510(k) Number | K230096 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 13, 2023 |
| Decision Date | May 23, 2023 |
| Days to Decision | 130 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
| Product Code | QDQ — Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 892.2090 |
| Definition | A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User. |